Pierrel S.p.A. : Board of Directors Meeting

PRESS RELEASE

The Board of Directors of Pierrel S.p.A.

Milan, 18 January 2012 - The Board of Directors of Pierrel S.p.A., has today acknowledged the resignation of Canio Giovanni Mazzaro as CEO of Pierrel S.p.A., and conferred all the operational appropriate powers to new General Director, Fulvio Citaredo.

The Board of Directors redefined the powers of Canio Mazzaro, who keeps the office of Chairman of Pierrel S.p.A.. and who will also carry on the coordination and the supervision of the activities of the General Director as well as of the members of the Board possibly granted with powers. Canio Giovanni Mazzaro also undertakes the position of Investor Relator, therefore replacing Aurelio Matrone, who remains Board Member of Pierrel S.p.A...

The Board of Directors also approved, pursuant to article 2.6.2 of Italian Stock Exchange regulation, the Calendar of Corporate events of Pierrel S.p.A for the year 2012.

Date	Event
Week 8-14 March 2012	Board of Directors meeting to approve the Draft Parent Company Statements and Consolidated Financial Statements at 31 December 2011
Week 23-30 April 2012	Shareholder's Meeting to approve Financial Statements at 31 December 2011
Week 8-15 May 2012	Board of Directors meeting to approve interim Financial Statements at 31 March 2012
Week 1-7 August 2012	Board of Directors meeting to approve First Half Results at 30 June 2012
Week 8-14 November 2012	Board of Directors meeting to approve the Interim Financial Statements at 30 September 2012

Any changes to the mentioned dates will be communicated to the market in a timely fashion.

Pierrel S.p.A.
Pierrel S.p.A., a global provider to the pharmaceutical and life science industries, specialized in Clinical Research (Contract Research), pharmaceutical production Contract Manufacturing) and development, registration and licensing of new drugs or formulations (Pierrel Pharma), is listed in the Italian Stock Exchange market. The Pierrel Group enjoys over 60 years experience in the pharmaceutical sector and is one of the main European manufacturers of local and dental anaesthetic drug products. The CRO division, Pierrel Research, with over 20 subsidiaries, operates both in Europe and USA, providing consultancies and full services for research and development of new molecules and drug products. The manufacturing plant in Capua, near Naples (Italy), has been authorized by FDA for the production of sterile small volumes parenteral drugs. Pierrel Pharma has recently obtained the NDA approval of its dental anaestetic Orabloc® in Canada , USA and Russia. Pierrel S.p.A Corporate office is located in Milan, Italy.
For further information: Pierrel S.p.A.
Investor Relator
Ingegner Canio G. Mazzaro
Email: [e-mail]. [phone]
fax [phone]
Image Building
Media Relations
Simona Raffaelli, Emanuela Borromeo, Claudia Arrighini
E-mail: [e-mail]
Tel. [phone]